Collegium Total Current Liabilities from 2010 to 2024
| COLL Stock | USD 30.50 0.21 0.68% |
Total Current Liabilities | First Reported 2013-12-31 | Previous Quarter 461.7 M | Current Value 459.4 M | Quarterly Volatility 162.8 M |
Check Collegium Pharmaceutical financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Collegium Pharmaceutical's main balance sheet or income statement drivers, such as Depreciation And Amortization of 156.7 M, Interest Expense of 87.5 M or Selling General Administrative of 97.6 M, as well as many indicators such as Price To Sales Ratio of 1.74, Dividend Yield of 0.0721 or PTB Ratio of 5.18. Collegium financial statements analysis is a perfect complement when working with Collegium Pharmaceutical Valuation or Volatility modules.
Collegium | Total Current Liabilities |
Latest Collegium Pharmaceutical's Total Current Liabilities Growth Pattern
Below is the plot of the Total Current Liabilities of Collegium Pharmaceutical over the last few years. Total Current Liabilities is an item on Collegium Pharmaceutical balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of Collegium Pharmaceutical are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. It is the total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations. Collegium Pharmaceutical's Total Current Liabilities historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Collegium Pharmaceutical's overall financial position and show how it may be relating to other accounts over time.
| Total Current Liabilities | 10 Years Trend |
|
Total Current Liabilities |
| Timeline |
Collegium Total Current Liabilities Regression Statistics
| Arithmetic Mean | 139,753,050 | |
| Geometric Mean | 35,729,055 | |
| Coefficient Of Variation | 118.86 | |
| Mean Deviation | 138,260,453 | |
| Median | 31,488,000 | |
| Standard Deviation | 166,104,211 | |
| Sample Variance | 27590.6T | |
| Range | 478.2M | |
| R-Value | 0.91 | |
| Mean Square Error | 5346.5T | |
| R-Squared | 0.82 | |
| Slope | 33,634,783 | |
| Total Sum of Squares | 386268.5T |
Collegium Total Current Liabilities History
About Collegium Pharmaceutical Financial Statements
Collegium Pharmaceutical investors utilize fundamental indicators, such as Total Current Liabilities, to predict how Collegium Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
| Last Reported | Projected for Next Year | ||
| Total Current Liabilities | 457.9 M | 480.8 M |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out the analysis of Collegium Pharmaceutical Correlation against competitors. For more information on how to buy Collegium Stock please use our How to buy in Collegium Stock guide.You can also try the Portfolio File Import module to quickly import all of your third-party portfolios from your local drive in csv format.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Collegium Pharmaceutical. If investors know Collegium will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Collegium Pharmaceutical listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.49) | Earnings Share 2.34 | Revenue Per Share 18.538 | Quarterly Revenue Growth 0.165 | Return On Assets 0.0968 |
The market value of Collegium Pharmaceutical is measured differently than its book value, which is the value of Collegium that is recorded on the company's balance sheet. Investors also form their own opinion of Collegium Pharmaceutical's value that differs from its market value or its book value, called intrinsic value, which is Collegium Pharmaceutical's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Collegium Pharmaceutical's market value can be influenced by many factors that don't directly affect Collegium Pharmaceutical's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Collegium Pharmaceutical's value and its price as these two are different measures arrived at by different means. Investors typically determine if Collegium Pharmaceutical is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Collegium Pharmaceutical's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.